Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre

Background ABP 980 is a biosimilar antibody to reference trastuzumab (RTZ). Aim of the following study is to confirm the similarity of ABP 980 and RTZ in terms of clinical efficacy and safety in patients with HER2-positive early breast cancer (EBC) undergoing neoadjuvant trastuzumab-containing chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matovina, Sabine, Engler, Tobias, Volmer, Lea-Louise, Müller, Heike, Grischke, Eva-Maria, Staebler, Annette, Hahn, Markus, Brucker, Sara Yvonne, Hartkopf, Andreas Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442908/
https://www.ncbi.nlm.nih.gov/pubmed/37614685
http://dx.doi.org/10.1055/a-1963-7511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442908/
https://www.ncbi.nlm.nih.gov/pubmed/37614685
http://dx.doi.org/10.1055/a-1963-7511

Ejemplares similares